Patent Number: 8,501,682

Title: Difluorinated tripeptides as HCV serine protease inhibitors

Abstract: The present invention relates to compounds of Formula I, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: ##STR00001## which inhibit serine protease activity, particularly the activity of hepatitis c virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis c virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

Inventors: Gai; Yonghua (North Grafton, MA), Or; Yat Sun (Watertown, MA), Wang; Zhe (Hockessin, DE)

Assignee: Enanta Pharmaceuticals, Inc.

International Classification: A61K 38/00 (20060101); A01N 37/18 (20060101)

Expiration Date: 2021-08-06 0:00:00